LINKÖPING, Sweden; October 3, 2019 – AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease.
Two abstracts highlighting the power of AMRA’s technology have been accepted by AASLD for presentation at The Liver Meeting® 2019 in Boston, Massachusetts. AMRA will present key insights and findings on the utility of MRI-based muscle composition assessments on patients with non-alcoholic fatty liver disease (NAFLD) using data from the large UK Biobank Imaging Study.
Sarcopenia is a common complication among those with cirrhosis and end-stage liver disease and may be predictive of comorbidities and prognosis, however, a consistent and objective definition is lacking. AMRA’s technology was used to assess muscle composition in participants with NAFLD to assess its potential for developing a standardized clinical definition of sarcopenia and for tracking and predicting disease progression.
In a study of 9 615 participants, AMRA revealed higher clinical relevance of assessing the deviation from expected muscle volume rather than measuring muscle volume directly. Combining deviation from muscle volume and muscle fat infiltration assessment provides a more exhaustive, muscle-specific description linked to function enabling objective evaluation of sarcopenia-related problems within NAFLD.
The approach was then used in a sub-study of 1 196 NAFLD participants, which revealed that Type II Diabetes (T2D) and Coronary Heart Disease (CHD) was 2-3 times more prevalent in NAFLD participants with adverse muscle composition (upper left corner of figure) compared to other NAFLD participants demonstrating that muscle composition evaluated using MRI could be used to effectively assess sarcopenia-related complications.
These studies will be discussed in detail through an oral and poster presentation at The Liver Meeting® next month.
On the Definition of Sarcopenia within NAFLD – Results from the large UK Biobank Imaging Study
Session: Parallel 35: NAFLD and NASH: Epidemiology and Outcomes
Date & Time: Monday, November 11, 2:00 PM
Location: Constitution Ballroom, Hynes Convention Center
Adverse Muscle Composition within NAFLD is Associated with Increased Comorbidity – Results from the large UK Biobank Imaging Study
Location: Hynes Convention Center, Hall B
Poster Sessions Date & Time
Friday, November 8: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Saturday, November 9: 2:00 pm–7:00 pm; Presenters Available: 5:15 – 6:15pm
Sunday, November 10: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Monday, November 11: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Attend AMRA’s presentations and connect with our team at AASLD’s The Liver Meeting® in November to learn more about our research and technology.
For further information, please contact:
SVP Global Business Development & Marketing